Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mouth Neoplasms 1Lymphedema 1HIV Infections 1Fallopian Tube Neoplasms 1Eyelid Sebaceous Gland Carcinoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Anus Neoplasms 1

Interventions

Oxaliplatin 146Fluorouracil 137Capecitabine 122Leucovorin 106Irinotecan 85Radiotherapy 67Bevacizumab 64Cetuximab 46Folfox protocol 28Surgical Procedures, Operative 23Radiation 23Drug Therapy 22Panitumumab 19XELOX 18Chemotherapy, Adjuvant 15Neoadjuvant Therapy 14Radiotherapy, Intensity-Modulated 13Chemoradiotherapy 13Magnetic Resonance Spectroscopy 11regorafenib 10Nivolumab 10Floxuridine 10sintilimab 8raltitrexed 8Specimen Handling 8IFL protocol 8Celecoxib 8Biopsy 8trifluridine tipiracil drug combination 7tislelizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Rectal Neoplasms × Sentinel Lymph Node Biopsy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡